experimental cryptococcosis
Recently Published Documents


TOTAL DOCUMENTS

49
(FIVE YEARS 5)

H-INDEX

17
(FIVE YEARS 1)

mBio ◽  
2022 ◽  
Author(s):  
Charles A. Specht ◽  
E. Jane Homan ◽  
Chrono K. Lee ◽  
Zhongming Mou ◽  
Christina L. Gomez ◽  
...  

Cryptococcosis, due to infection by fungi of the Cryptococcus neoformans species complex, is responsible for substantial morbidity and mortality in immunocompromised persons, particularly those with AIDS. Cryptococcal vaccines are a public health priority yet are not available for human use.


2021 ◽  
Author(s):  
Charles Specht ◽  
E. Jane Homan ◽  
Chrono K Lee ◽  
Zhongming Mou ◽  
Christina L Gomez ◽  
...  

The high global burden of cryptococcosis has made development of a protective vaccine a public health priority. We previously demonstrated that a vaccine composed of recombinant Cryptococcus neoformans chitin deacetylase 2 (Cda2) delivered in glucan particles (GPs) protects BALB/c and C57BL/6 mice from an otherwise lethal challenge with a highly virulent C. neoformans strain. An immunoinformatic analysis of Cda2 revealed a peptide sequence predicted to have strong binding to the MHC Class II (MHC II) H2-IAd allele found in BALB/c mice. BALB/c mice vaccinated with GPs containing a 32 amino acid peptide (Cda2-Pep1) that included this strong binding region were protected from cryptococcosis. Protection was lost with GP-based vaccines containing versions of recombinant Cda2 protein and Cda2-Pep1 with mutations predicted to greatly diminish MHC II binding. Cda2 has homology to the three other C. neoformans chitin deacetylases, Cda1, Cda3 and Fpd1, in the high MHC II binding region. GPs loaded with homologous peptides of Cda1, Cda3 and Fpd1 protected BALB/c mice from experimental cryptococcosis, albeit not as robustly as the Cda2-Pep1 vaccine. Finally, seven other peptides were synthesized based on regions in Cda2 predicted to contain promising CD4+ T cell epitopes in BALB/c or C57BL/6 mice. While five peptide vaccines significantly protected BALB/c mice, only one protected C57BL/6 mice. Thus, GP-based vaccines containing a single peptide can protect mice against cryptococcosis. However, given the diversity of human MHC II alleles, a peptide-based Cryptococcus vaccine for use in humans would be challenging and likely need to contain multiple peptide sequences.


2021 ◽  
Vol 7 (6) ◽  
pp. 492
Author(s):  
Caroline Patini Rezende ◽  
Patricia Kellen Martins Oliveira Brito ◽  
Thiago Aparecido Da Silva ◽  
Andre Moreira Pessoni ◽  
Leandra Naira Zambelli Ramalho ◽  
...  

Cryptococcus neoformans, the causative agent of cryptococcosis, is the primary fungal pathogen that affects the immunocompromised individuals. Galectin-3 (Gal-3) is an animal lectin involved in both innate and adaptive immune responses. The present study aimed to evaluate the influence of Gal-3 on the C. neoformans infection. We performed histopathological and gene profile analysis of the innate antifungal immunity markers in the lungs, spleen, and brain of the wild-type (WT) and Gal-3 knockout (KO) mice during cryptococcosis. These findings suggest that Gal-3 absence does not cause significant histopathological alterations in the analyzed tissues. The expression profile of the genes related to innate antifungal immunity showed that the presence of cryptococcosis in the WT and Gal-3 KO animals, compared to their respective controls, promoted the upregulation of the pattern recognition receptor (PRR) responsive to mannose/chitin (mrc1) and a gene involved in inflammation (ccr5), as well as the downregulation of the genes related to signal transduction (card9, fos, ikbkb, jun) and PRRs (cd209a, colec12, nptx1). The absence of Gal-3, in fungal infection, a positively modulated gene involved in phagocytosis (sftpd) and negatively genes involved in signal transduction (syk and myd88), proinflammatory cytokines il-1β and il-12b and cd209a receptor. Therefore, our results suggest that Gal-3 may play an essential role in the development of antifungal immune responses against cryptococcosis.


Author(s):  
Herdson Renney de Sousa ◽  
Stefânia de Frazão ◽  
Getúlio Pereira de Oliveira Júnior ◽  
Patrícia Albuquerque ◽  
André Moraes Nicola

Cryptococcosis, an invasive mycosis caused by Cryptococcus spp, kills between 20% and 70% of the patients who develop it. There are no vaccines for prevention, and treatment is based on a limited number of antifungals. Studying fungal virulence and how the host responds to infection could lead to new therapies, improving outcomes for patients. The biggest challenge, however, is that experimental cryptococcosis models do not completely recapitulate human disease, while human experiments are limited due to ethical reasons. To overcome this challenge, one of the approaches used by researchers and clinicians is to: 1) collect cryptococcal clinical isolates and associated patient data; 2) study the set of isolates in the laboratory (virulence and host-pathogen interaction variables, molecular markers); 3) correlate the laboratory and patient data to understand the roles fungal attributes play in the human disease. Here we review studies that have shed light on the cryptococcosis pathophysiology using these approaches, with a special focus on human disease. Isolates that more effectively evade macrophage responses, that secrete more laccase, melanize faster and have larger capsules in the cerebrospinal fluid are associated with poorer patient outcomes. Additionally, molecular studies have also shown that cryptococcal clades vary in virulence, with clinical impact. Limitations of those studies include the use of a small number of isolates or retrospectively collected clinical data. The fact that they resulted in very important information is a reflection of the impact this strategy has in understanding cryptococcosis and calls for international collaboration that could boost our knowledge.


Vaccine ◽  
2020 ◽  
Vol 38 (3) ◽  
pp. 620-626 ◽  
Author(s):  
Maureen M. Hester ◽  
Chrono K. Lee ◽  
Ambily Abraham ◽  
Payam Khoshkenar ◽  
Gary R. Ostroff ◽  
...  

2018 ◽  
Vol 07 (01) ◽  
Author(s):  
Eriques Goncalves Silva ◽  
Josemar Neves Cavalcanti ◽  
Flavio Cesar Viani ◽  
Sandra Marilia de Souza Silva ◽  
Amanda Latercia Tranches Dias

Mycoses ◽  
2009 ◽  
Vol 20 (11) ◽  
pp. 409-422 ◽  
Author(s):  
R. M. Karaoui ◽  
Nancy K. Hall ◽  
H. W. Larsh

Mycoses ◽  
2009 ◽  
Vol 20 (10) ◽  
pp. 380-388 ◽  
Author(s):  
R. M. Karaoui ◽  
Nancy K. Hall ◽  
H. W. Larsh

2008 ◽  
Vol 181 (1) ◽  
pp. 566-573 ◽  
Author(s):  
Carmelo Biondo ◽  
Angelina Midiri ◽  
Maria Gambuzza ◽  
Elisabetta Gerace ◽  
Maria Falduto ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document